Mergers & Acquisitions Mergers & Acquisitions

Johnson & Johnson skips chance to amend TachoSil deal in bid for EU approval

By Natalie McNelis
  • 18 Mar 2020 23:46
  • 18 Mar 2020 15:06
Johnson & Johnson has passed up a chance to amend its bid to buy Takeda Pharmaceutical’s TachoSil, currently under review by the European Commission, MLex has learned.

The US health-products conglomerate had until midnight last night to submit amendments to the deal to address any competition concerns that the EU regulator might have

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News